If approved, aducanumab will still have hills to climb

As doctors digest Biogen’s aducanumab data, the possible approval of the first disease-modifying therapy for Alzheimer’s disease is raising questions around reimbursement and how to build the necessary infrastructure among physicians and hospitals.

While investors rewarded Biogen Inc. (NASDAQ:BIIB) for its late but welcome Phase III data, adding nearly $11 billion to its market cap, doctors are still making sense of the discordant results and how they might use aducanumab if it is approved (see “Biogen’s Aducanumab Pleases Investors, Confounds Doctors”)...